These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30508592)

  • 1. Remission from chronic opioid use-Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics.
    Ling W; Nadipelli VR; Ronquest NA; Albright VA; Aldridge AP; Learned SM; Mehra V; Heidbreder C
    Contemp Clin Trials; 2019 Jan; 76():93-103. PubMed ID: 30508592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.
    Ling W; Nadipelli VR; Aldridge AP; Ronquest NA; Solem CT; Chilcoat H; Albright V; Johnson C; Learned SM; Mehra V; Heidbreder C
    J Addict Med; 2020; 14(5):e233-e240. PubMed ID: 32187112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study.
    Craft WH; Tegge AN; Keith DR; Shin H; Williams J; Athamneh LN; Stein JS; Chilcoat HD; Le Moigne A; DeVeaugh-Geiss A; Bickel WK
    Drug Alcohol Depend; 2022 May; 234():109389. PubMed ID: 35287034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.
    Ling W; Nadipelli VR; Solem CT; Ronquest NA; Yeh YC; Learned SM; Mehra V; Heidbreder C
    J Addict Med; 2019; 13(6):442-449. PubMed ID: 30844878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.
    Frost M; Bailey GL; Lintzeris N; Strang J; Dunlop A; Nunes EV; Jansen JB; Frey LC; Weber B; Haber P; Oosman S; Kim S; Tiberg F
    Addiction; 2019 Aug; 114(8):1416-1426. PubMed ID: 31013390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Remission of Opioid Use Disorder in an Adolescent Using Buprenorphine Extended - Release Subcutaneous Injection: A Case Report.
    Schmuhl KK; Golec A; Ebersole AM
    J Adolesc Health; 2024 Jul; 75(1):200-202. PubMed ID: 38402472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study.
    Ling W; Nadipelli VR; Solem CT; Ronquest NA; Yeh YC; Learned SM; Mehra V; Heidbreder C
    J Subst Abuse Treat; 2020 Mar; 110():1-8. PubMed ID: 31952623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Cannabis Use Influence Opioid Outcomes and Quality of Life Among Buprenorphine Maintained Patients? A Cross-sectional, Comparative Study.
    Bagra I; Krishnan V; Rao R; Agrawal A
    J Addict Med; 2018; 12(4):315-320. PubMed ID: 29543612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
    Tompkins CNE; Neale J; Strang J
    J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine treatment for opioid use disorder: recent progress.
    Parida S; Carroll KM; Petrakis IL; Sofuoglu M
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):791-803. PubMed ID: 31232604
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term recovery from opioid use disorder: recovery subgroups, transition states and their association with substance use, treatment and quality of life.
    Craft WH; Shin H; Tegge AN; Keith DR; Athamneh LN; Stein JS; Ferreira MAR; Chilcoat HD; Le Moigne A; DeVeaugh-Geiss A; Bickel WK
    Addiction; 2023 May; 118(5):890-900. PubMed ID: 36524904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):35-37. PubMed ID: 29485976
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of buprenorphine treatment success of opioid dependence in two Baltimore City grassroots recovery programs.
    Damian AJ; Mendelson T; Agus D
    Addict Behav; 2017 Oct; 73():129-132. PubMed ID: 28505488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City.
    Truong C; Krawczyk N; Dejman M; Marshall-Shah S; Tormohlen K; Agus D; Bass J
    Addict Behav; 2019 Jun; 93():14-19. PubMed ID: 30682677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the delivery of buprenorphine for opioid dependence.
    Rosenthal RN; Goradia VV
    Drug Des Devel Ther; 2017; 11():2493-2505. PubMed ID: 28894357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.
    Laffont CM; Gomeni R; Heidbreder C; Jones JP; Nasser AF
    J Clin Pharmacol; 2016 Jul; 56(7):806-15. PubMed ID: 26479717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.